HLA matching in haploidentical related donor allogeneic hematopoietic cell transplantation
| Reference . | Consensus guidelines . | |||
|---|---|---|---|---|
| Ciurea et al31 (2020) | T-replete Haplo using ptCy-based GVHD prophylaxis: 1. Avoid DSA (MFI <1000) 2. Younger donor over older 3. Male donor for male recipient 4. Sibling or offspring over parent 5. Father preferred over mother 6. ABO match over minor over major mismatch | |||
| New research published, since release of guidelines | ||||
| Study | Population | Trial/study design | Comparison(s) | Key findings |
| Solomon et al32 (2020) | N = 208 consecutive first alloHCT for hematologic malignancy receiving T-cell replete Haplo with ptCy GVHD prophylaxis | Observational—single center | 1. Total number of mismatches 2. Individual locus match/mismatch effects on outcomes | 1. HLA-DRB1 and HLA-DPB1 nonpermissive mismatch independently associated with improved OS 2. HLA-A mismatch increased chronic GVHD |
| Fuchs et al34 (2022) | N = 1484, first alloHCT for ALL, AML, or MDS, adult patients receiving T-cell replete Haplo with ptCy-based GVHD prophylaxis | Observational—multicenter | 1. Total number of mismatches 2. Individual locus match/mismatch effects on outcomes | 1. No association with number of mismatches 2. HLA-B leader match improves OS and DFS; HLA-DRB1 GVH vector mismatch decreases relapse and improves DFS; HLA-DPB1 nonpermissive mismatch improves OS and DFS; HLA-C match decreases chronic GVHD |
| Reference . | Consensus guidelines . | |||
|---|---|---|---|---|
| Ciurea et al31 (2020) | T-replete Haplo using ptCy-based GVHD prophylaxis: 1. Avoid DSA (MFI <1000) 2. Younger donor over older 3. Male donor for male recipient 4. Sibling or offspring over parent 5. Father preferred over mother 6. ABO match over minor over major mismatch | |||
| New research published, since release of guidelines | ||||
| Study | Population | Trial/study design | Comparison(s) | Key findings |
| Solomon et al32 (2020) | N = 208 consecutive first alloHCT for hematologic malignancy receiving T-cell replete Haplo with ptCy GVHD prophylaxis | Observational—single center | 1. Total number of mismatches 2. Individual locus match/mismatch effects on outcomes | 1. HLA-DRB1 and HLA-DPB1 nonpermissive mismatch independently associated with improved OS 2. HLA-A mismatch increased chronic GVHD |
| Fuchs et al34 (2022) | N = 1484, first alloHCT for ALL, AML, or MDS, adult patients receiving T-cell replete Haplo with ptCy-based GVHD prophylaxis | Observational—multicenter | 1. Total number of mismatches 2. Individual locus match/mismatch effects on outcomes | 1. No association with number of mismatches 2. HLA-B leader match improves OS and DFS; HLA-DRB1 GVH vector mismatch decreases relapse and improves DFS; HLA-DPB1 nonpermissive mismatch improves OS and DFS; HLA-C match decreases chronic GVHD |
MFI, mean fluorescence intensity.